关于罗格列酮心血管安全性的疑问

[Doubts as to the cardiovascular safety of rosiglitazone].

作者信息

Hoekstra J B L, Bossuyt P M M, de Vries J H

机构信息

Academisch Medisch Centrum/Universiteit van Amsterdam, Postbus 22.660, 1100 DD Amsterdam.

出版信息

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1449-50.

PMID:17633972

Abstract

Recently, it was observed that rosiglitazone increased the risk of myocardial infarction. The American Food and Drug Administration therefore issued a safety alert. The practice guideline 'Diabetes mellitus type 2' of the Dutch College of General Practitioners only leaves room for the use of another thiazolidinedione, pioglitazone, and even that advice has been questioned. The new information on the serious adverse effects of rosiglitazone may further reduce the willingness to prescribe this drug for patients with type 2 diabetes.

摘要

最近，有人观察到罗格列酮会增加心肌梗死的风险。因此，美国食品药品监督管理局发布了一项安全警报。荷兰全科医生学院的“2型糖尿病”实践指南只允许使用另一种噻唑烷二酮类药物——吡格列酮，甚至这一建议也受到了质疑。关于罗格列酮严重不良反应的新信息可能会进一步降低为2型糖尿病患者开具此药的意愿。